NASDAQ:NVCRNovocure Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novocure Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $63.34 -2.94 (-4.44 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$62.80Now: $63.34▼$65.7650-Day Range$57.05MA: $73.97▼$95.7552-Week Range$41.51Now: $63.34▼$98.84Volume1.05 million shsAverage Volume1.25 million shsMarket Capitalization$6.31 billionP/E RatioN/ADividend YieldN/ABeta1.97 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingNovocure has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $87.40, Novocure has a potential upside of 38.0% from its current price of $63.34.Amount of Analyst CoverageNovocure has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesNovocure has received 412 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovocure has received 388 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovocure has received 51.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote “Outperform” if you believe NVCR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovocure does not currently pay a dividend.Dividend GrowthNovocure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novocure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,574,374.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Novocure is held by insiders.Percentage Held by Institutions69.47% of the stock of Novocure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Novocure are expected to grow by 180.00% in the coming year, from $0.45 to $1.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novocure is -791.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novocure is -791.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovocure has a P/B Ratio of 28.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.76 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR Previous Symbol CUSIPN/A CIK1645113 Webhttp://www.novocure.com/ Phone44-0-15-3475-6700Debt Debt-to-Equity Ratio0.75 Current Ratio5.10 Quick Ratio4.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio140.76 P/E GrowthN/A Sales & Book Value Annual Sales$351.32 million Price / Sales17.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book28.79Profitability EPS (Most Recent Fiscal Year)($0.07) Net Income$-7,230,000.00 Net Margins-2.06% Return on Equity-4.17% Return on Assets-1.70%Miscellaneous EmployeesN/A Outstanding Shares99,640,000Market Cap$6.31 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive NVCR News and Ratings via Email Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NVCR Rates by TradingView Novocure (NASDAQ:NVCR) Frequently Asked Questions How has Novocure's stock been impacted by COVID-19 (Coronavirus)? Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has decreased by 6.0% and is now trading at $63.34. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Novocure? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure. When is Novocure's next earnings date? Novocure is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novocure. How were Novocure's earnings last quarter? Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, February, 27th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. The medical equipment provider earned $99.23 million during the quarter, compared to analyst estimates of $99.10 million. Novocure had a negative return on equity of 4.17% and a negative net margin of 2.06%. The business's revenue was up 42.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) EPS. View Novocure's earnings history. What guidance has Novocure issued on next quarter's earnings? Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million. What price target have analysts set for NVCR? 6 equities research analysts have issued 1-year price targets for Novocure's stock. Their forecasts range from $79.00 to $97.00. On average, they anticipate Novocure's share price to reach $87.40 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View analysts' price targets for Novocure. Has Novocure been receiving favorable news coverage? News headlines about NVCR stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNovocure. Who are some of Novocure's key competitors? Some companies that are related to Novocure include DexCom (DXCM), ResMed (RMD), FRESENIUS SE &/S (FSNUY), Teleflex (TFX), Insulet (PODD), Hill-Rom (HRC), ABIOMED (ABMD), Penumbra (PEN), Haemonetics (HAE), ICU Medical (ICUI), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO) and NuVasive (NUVA). What other stocks do shareholders of Novocure own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), NVIDIA (NVDA) and Roper Technologies (ROP). Who are Novocure's key executives? Novocure's management team includes the following people: Asaf Danziger, Chief Executive Officer & DirectorMike Ambrogi, Chief Operating OfficerWilco Groenhuysen, CFO & Chief Accounting OfficerEilon D. Kirson, Chief Science Officer, Head-Research & DevelopmentUri Weinberg, Vice President-Clinical Development What is Novocure's stock symbol? Novocure trades on the NASDAQ under the ticker symbol "NVCR." How do I buy shares of Novocure? Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Novocure's stock price today? One share of NVCR stock can currently be purchased for approximately $63.34. How big of a company is Novocure? Novocure has a market capitalization of $6.31 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. View additional information about Novocure. What is Novocure's official website? The official website for Novocure is http://www.novocure.com/. How can I contact Novocure? Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is the cash asset ratio?
